BioStem announced that it has received the TRIP (TRG Rapid Inquiry Program) response from the FDA’s Tissue Reference Group (TRG) for the Company’s amniotic membrane allograft, VENDAJE™
BioStem Technologies, Inc. announced it engaged D. Brooks and Associates CPA's, P.A. as the Company’s PCAOB registered certified public accounting firm for the 2020 and 2019 fiscal years.
BioStem Technologies today announced, in partnership with Veterans Medical Distributors Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), that it has been awarded a five-year Federal Supply Schedule (FSS) contract for its VENDAJE™ line of amnion membrane allografts, by the U.S. Department of Veterans Affairs (VA).
BioStem Life Sciences has signed a Master Service Agreement with a new customer to manufacture the customer’s amniotic membrane platform for the next two years
BioStem Technologies today announced that it expects to file its annual and quarterly reports for the years 2018, 2019 and 2020 to become current with OTC Markets in late 2020.
BioStem Technologies today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes.
